About Marinus Pharma
Marinus Pharma is a Healthcare company based in Radnor (United States) founded in 2003, and was acquired by Immedica in December 2024. Developer of therapeutics to treat seizure disorders. Marinus Pharma has raised $71.58 million across 5 funding rounds from investors including Canaan, Immedica and Southern New Hampshire Health. Marinus Pharma offers products and services including Ganaxolone. Its focus areas include Life Sciences, Neurology, Drugs and Epilepsy. Its legal entity is Marinus Pharmaceuticals, Inc. Its competitors include GenEp, Epygenix and Neuroene Therapeutics; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2003, Marinus Pharma is based in Radnor, United States, where pharmaceuticals targeting seizure disorders are developed. The lead product, Ganaxolone, is provided in intravenous and oral forms for addressing status epilepticus and rare orphan epilepsies. Operations encompass drug development within the neurology sector, alongside advocacy and associated initiatives.
Products & Services of Marinus Pharma
Marinus Pharma offers a comprehensive portfolio of products and services, including Ganaxolone.
Medication for treating severe epilepsy and seizure disorders.
Apps and channels of Marinus Pharma
its YouTube channel Marinus Pharma has 76 subscribers and 22 videos.
Videos from Marinus Pharma
The most watched videos on Marinus Pharma's YouTube channel, Marinus Pharma (76 subscribers). Click a video to play it here.
More on Marinus Pharma.
Funding Insights of Marinus Pharma
Marinus Pharma has successfully raised a total of $71.58M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.23 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71.58M
- Total Rounds 5
- Last Round Post-IPO — $1.23M
- First Round $29.4M
(Oct 2005)
- Investors Count 6
All 5 funding rounds of Marinus Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $1.23M | Post-IPO | – | – | – |
| Dec 2019 | $30M | Post-IPO | – | – | – |
| Jul 2013 | $21.77M | Series C | – | – | |
| Apr 2009 | $20.41M | Series B | – | Canaan, Domain Associates | – |
| Oct 2005 | $29.4M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Marinus Pharma
Marinus Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaan, Immedica and Southern New Hampshire Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Healthcare investments are managed by corporate-backed venture capital fund RusnanoMedInvest. | rmi.com.ru | Moscow, Russia | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Early-stage tech startups are funded by this venture capital firm. | flarecapital.com | Boston, United States | ||
Comprehensive health services are provided in southern New Hampshire. | 1891 | snhhealth.org | Nashua, United States | |
Therapeutic agents for oncology, neurology, and related diseases are developed. | 2017 | immedica.com | Stockholm, Sweden |
Investor details for Marinus Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Marinus Pharma
39 people are tracked at Marinus Pharma (12 in leadership, 15 in board & advisors, 12 in team).
| Name | Role | Group |
|---|---|---|
Karen Einbinder | Senior Director, Market Access & Reimbursement | Leadership |
Gabe Smith - Mba | Director, Program Management | Leadership |
Nicholas Sulham | Vp, Commercial Operations | Leadership |
Kristin Rudisill | Vice President, Business Unit Lead Acute Care Franchise | Leadership |
Henri Vaitkevicius | Vice President Clinical Development | Leadership |
Debra Mohollen | Vice President, Finance And Controller | Leadership |
David A. Czekai | VP, Manufacturing | Leadership |
Vanessa Costa | Executive Director, Corporate Compliance | Leadership |
Andrew Stasiak | Senior Director Gxp Quality Assurance | Leadership |
Colleen Mullenix | Senior Director, Business Operations, Clinical Development | Leadership |
Marc Bellisario | Executive Director, R&d Program Management | Leadership |
Heather van Heusen | Director, Clinical Development Operations | Leadership |
Nicola Specchio | Scientific Advisory Board Member | Board & advisors |
Elizabeth Thiele | Scientific Advisory Board Member | Board & advisors |
Aatif M. Husain | Scientific Advisory Board Member | Board & advisors |
Enrique J. Carrazana | Director | Board & advisors |
Tim M. Mayleben | Lead Independent Director | Board & advisors |
Sara Nochur | Director | Board & advisors |
Lawrence Hirsch | Scientific Advisory Board Member | Board & advisors |
Michael Rogawski | Scientific Advisory Board Member | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Marinus Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Marinus Pharma
5 dated milestones of Marinus Pharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Marinus Pharma is founded.
- Funding First funding round of $29.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.2M.
- Exit Acquired by Immedica.
Competitors of Marinus Pharma
Marinus Pharma has 3 listed competitors in our database, 1 of them funded. They include GenEp, Epygenix and Neuroene Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genepbio.com | 2021 | Charlottesville, United States | $10.4M | Therapeutics for epilepsy are developed targeting ion channel mutations. | ||
| epygenix.com | 2016 | Paramus, United States | Develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions. | |||
| neuroenetherapeutics.com | 2015 | Charleston, United States | Novel Vitamin K-based therapeutics for epilepsy are developed. |
Detailed competitors of Marinus Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Marinus Pharma
The website of Marinus Pharma (marinuspharma.com) receives about 2.4K visits a month and ranks #5,529,430 among all websites worldwide, #6,120 in Biotechnology and Pharmaceuticals.
- Monthly visits2.4K
▼ 19.9% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,529,430
among all websites
- Category rank#6,120
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.8
- Average visit32 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Marinus Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| voyagertherapeutics.com | 100% | 8.8K | #2,249,869 | View details | |
investor.ironwoodpharma.com | investor.ironwoodpharma.com | 98% | – | ||
| nbpharma.com | 96% | 1.6K | #7,824,941 | View details | |
| janssenpharmaceuticalsinc.com | 95% | View details | |||
| amylin.com | 95% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Marinus Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Marinus Pharma (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Marinus Pharma
Complete news archive for Marinus Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Marinus Pharma
Marinus Pharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Marinus Pharma is headquartered in Radnor, United States. It is registered at Radnor, Pennsylvania, United States.
Marinus Pharma is a funded company, having raised a total of $71.58M across 5 funding rounds to date. The company's 1st funding round was a Series A of $29.4M, raised on Oct 2005.
Founded in 2003, Marinus Pharma is based in Radnor, United States, where pharmaceuticals targeting seizure disorders are developed. The lead product, Ganaxolone, is provided in intravenous and oral forms for addressing status epilepticus and rare orphan epilepsies. Operations encompass drug development within the neurology sector, alongside advocacy and associated initiatives.
Marinus Pharma's top competitors include GenEp, Neuroene Therapeutics and Epygenix.
Marinus Pharma offers Ganaxolone.
Marinus Pharma has 7 investors. Key investors include Canaan, Immedica, Southern New Hampshire Health, Sofinnova, and RusnanoMedInvest.
Marinus Pharma operates through Marinus Pharmaceuticals, Inc..
Yes. Marinus Pharma was acquired by Immedica in December 2024.